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1. SUMMARY 
Two recent warnings by the US Food and Drug Administration (FDA) relating to 
severe side-effects led to discussions concerning the biocompatibility requirements of 
surgical meshes. There are currently no standardized tools for the comparison of surgical 
meshes. 
Our aim was to develop a standardized and manufacturer-independent in vitro test 
system for the adherence performance of tissue clusters (fibroblasts, endothelial cells and 
muscle-derived cells) as a marker for the biocompatibility of commercially available meshes. 
In this test system, we could establish a repeatable ranking of meshes with regard to their 
biocompatibility. The adherence behavior was independent of the individual patient features, 
suggesting that the biological behavior of a mesh is probably conditioned by the structure of 
the biomaterial or/and its chemical composition rather than by individual host 
characteristics/features. This in vitro test system has been shown to be a feasible pattern for 
the investigation of different mesh coating strategies. The coating of meshes prior to 
cultivation, e.g. with peripheral blood mononuclear cells (PBMCs), did not affect the 
adherence score, whereas coating with platelets and blood plasma increased the score, 
suggesting improved biocompatibility in vitro. Plasma coating exhibited the greatest potential 
to improve the in vitro adherence score. The previous ranking of native meshes remained 
consistent after coating, but established at a higher level. 
In order to explore the predictive value and validity of the test system and also newly 
tested coating strategies, we translated the preliminary in vitro results into in vivo 
circumstances and conducted a large-animal experiment on sheep. The entire experimental 
approach followed the recently developed recommendations of the IDEAL (Innovation, 
Development Exploration, Assessment and Long-term) study for surgical innovations. In this 
long-term animal study, we demonstrated that our recently developed in vitro test system may 
predict the in vivo performances of the meshes. This effect was independent of the location of 
the mesh in the body, although its particular extent varies with the site of implantation. The 
coating of meshes with autologous plasma prior to implantation had positive effects on the 
biocompatibility of meshes in vivo. Investigation of the ultra-short-term determinants of the 
foreign body reaction (FBR) at the implant site in vivo revealed that the local inflammatory 
reaction is an early and susceptible event after mesh implantation. It cannot be influenced by 
prior plasma coating and does not depend on the localization of implantation. The project is 
continuing, the method currently being implemented in humans. 
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2. INTRODUCTION 
2.1. Biocompatibility and surgical meshes 
The mechanical and biocompatibility properties of synthetic materials used to replace 
or support native tissues play a crucial role in their in vivo function. An ideal graft material is 
expected to be chemically inert, non-toxic, non-allergic, non-inflammatory, resistant to 
infection, non-carcinogenic, solid, sterilizable and convenient and affordable.
2
 
Biocompatibility is defined as “the ability of a material to perform with an appropriate 
host response in a specific situation”, implying a symbiotic relationship of acceptance 
between the host and the respective implanted material.
3
 For a material to perform best, it 
needs to be integrated properly into the tissue, to generate an appropriate inflammatory 
response and to maintain mechanical integrity (keep its shape). These qualities are discussed 
along with additional and host-related factors that contribute to biocompatibility. As 
biocompatibility is described by the FBR at the host-tissue/biomaterial interface, three crucial 
steps have been identified that describe the time course of the FBR: protein absorption, cell 
recruitment and, finally, fibrotic encapsulation and extracellular matrix formation. The 
dynamics of the FBR is greatly influenced by the biomaterial composition, and in particular 
the type of polymer, the material weight, the filament structure and the pore size. In this 
regard, Amid proposed a standardized classification system to distinguish between different 
types of synthetic meshes, in particular emphasizing the physical properties of biomaterials 
and their predictable impact on possible adverse events (Table 1).
4
 They classified meshes 
into 4 different groups, focussing mainly on the respective pore size. They assumed that the 
utilization of meshes from the different groups has a prognostic value for different adverse 
events, such as the risk of infection, seroma formation and fistula formation, and may 
therefore be used as predictors for biocompatibility. They recommended that the 
classification should influence the clinical decision as to which alloplastic material to apply 
in a particular clinical situation. In accordance with those early results, it is currently accepted 
that large porous meshes lead to the best tissue integration and, thanks to the reduced surface 
area, produce the least FBR, inflammation and fibrosis. Small-pore or microporous and foil- 
or layer-like mesh modifications, however, are associated with a significantly greater FBR 
and inflammation frequently related with the phenomenon of bridging, which finally may 
cause a significant contraction or shrinkage of the mesh. Polypropylene (PP), polyethylene 
terephthalate (PET) and polytetrafluoroethylene (PTFE) are currently the most commonly 
used mesh materials, whereas PP seems to be the most frequently used polymer for the 
construction of surgical meshes.
5
 There appears to be a trend in current mesh development 
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toward minimization of the mesh density and the use of macroporous weave patterns of 
monofilament PP.
6
 In a review analyzing the mechanical properties of and the tolerance to 
synthetic implants for stress urinary incontinence (SUI) and pelvic organ prolapsed (POP), 
Cosson et al. identified PP (known to offer durability and elasticity) as the most promising 
material for those indications.
7
 Biocompatibility assessment of alloplastic materials through 
the use of appropriate cell cultures in vitro is a valid and accepted method which furnishes 
information about the toxicity of the investigated material, and the possible effects on the 
metabolism and growth of the cells.
8
 Although cells can be sensitively characterized with this 
method, and the conditions can easily be standardized, no complex tissue representative of 
the human body has yet been investigated.  
 
Table 1. The Amid classification 
 Characteristics Examples 
1 A completely macroporous mesh, >75 µm Prolene 
Marlex 
Atrium 
Trelex 
2 A completely microporous mesh, <10 µm Gore-Tex surgical membranes 
3 A macroporous patch with multifilaments or a 
microporous component 
Mersilene (woven Dacron)  
Teflon (PTFE) 
Surgipro (woven PP) 
MycroMesh (perforated PTFE) 
4 Submicronic pores, often associated with type 1 
materials to prevent adhesion (e.g. peritoneum) 
Silastic 
Celigard 
Dura mater substitute 
 
2.2. Foreign body reaction 
When implanted for a particular indication, a mesh represents a foreign body which 
induces a FBR, which is an important surrogate for its biocompatibility performance. This 
reaction is triggered by the initial acute phase reaction and the subsequent construction of the 
implant matrix, mostly conducted by the migration of fibroblasts producing 
glycosaminoglycans and collagen. The FBR has been histologically described as a foreign 
body granuloma adjacent to the mesh fiber and a surrounding collagen capsule that shields 
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the host from the foreign material. It seems likely that such a chronic inflammatory process 
impairs normal wound healing and tissue regeneration and may result in reduced 
functionality and increased side-effects when applied clinically.
9
 A considerable influence on 
the dynamics of the FBR is exerted by the biomaterial composition, and in particular the type 
of polymer, the material weight, the filament structure and the pore size. 
However, the process of FBR does not necessarily reduce the proposed mesh function 
of restoring mechanical functionality in a particular region of the body. Several attempts have 
been made to improve the biocompatibility of meshes and reduce the FBR.
10, 11
 The exact 
FBR mechanisms and respective time flow in vivo are not entirely understood, but the rapid 
accumulation of huge numbers of phagocytic cells, and especially blood monocytes and 
tissue-derived macrophages, play a crucial role in it.
12-14
 Additionally, the transcriptionally-
induced overexpression of the matrix metalloproteinases-2 (MMP-2) seems to play a key role 
in the FBR.
15-18
 New therapeutic strategies may target cellular and molecular interactions 
during these phases, influencing the complex cascade of immune modulators, soluble 
mediators and different cell types. A beneficial effect of gentamycin on a chronic FBR by 
modulation of MMP-2 gene transcription has recently been described, which may be a 
feasible approach to the optimization of mesh integration into the abdominal wall, and 
ultimately to improvement of the long-term outcome following hernia mesh repair.
19
 
 
2.3. Application of surgical meshes and current controversies 
Alloplastic materials such as meshes are widely applied in surgical approaches for 
hernia, incontinence and prolapse situations. The development of meshes is an ongoing 
process characterized by changes in polymer structure, biocompatibility, operative handling 
and costs. A good mesh should provoke a negligible FBR with no pathologic fibrosis at a 
decreased risk of infection. In a Public Health Notification issued in 2008, the FDA reported 
more than 1000 unexpected and severe adverse events, mostly associated with transvaginal 
placement of a surgical mesh to treat POP and SUI.
20
 In 2011, a second FDA warning was 
announced on the basis of 2,874 newly identified Medical Device Reports: 1,503 associated 
with POP repairs, and 1,371 associated with SUI repairs.
21
 Factors involved included the 
overall health of the patient, the surgical technique used and concomitant procedures 
undertaken; particular importance was attached to the mesh material and the size and shape of 
the mesh as causes of adverse events. However, the search for the optimal mesh for a 
particular indication, with high functionality and biocompatibility and a minimized side-
effect profile in the short-term and long-term follow-up remains difficult. These two FDA 
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warnings have led to several regulatory changes for surgical meshes, including the upgrading 
of risk classifications, requirements for clinical studies to address the risks and benefits of 
meshes used to treat POP and SUI and the expanded post-market monitoring of device 
performance.
21
 
 
2.4. The IDEAL recommendations 
In the assessment of quality standards for surgical meshes, comparability with other 
meshes with regard to quality and stage of development should be possible. Despite the 
existence of several models for the assessment of different meshes with regard to their 
particular biomechanical characteristics, there are currently virtually no standardized tools for 
comparisons among meshes.
22, 23
 Many alloplastic materials are still being used without 
proper trials and are recommended by manufacturers rather than on the basis of data arising 
from in vitro or in vivo experiences. Once a product is on the market, financial support for 
further investigations decreases and ongoing evaluation with unknown results is often not 
desired. Thus, as compared with the strict regulations for drug development and market 
implementation, the process of adopting and improving surgical innovations (e.g. meshes) is 
still unregulated, unstructured and variable. In 2009, the Lancet dedicated a series to the topic 
of ”Surgical Innovation and Evaluation” and its current status.24-26 A five-stage description of 
the surgical development process has been proposed, the IDEAL model which allows the 
assignment of every surgical innovation, e.g. surgical technique, alloplastic materials, etc., to 
its particular corresponding step of development. The IDEAL framework, has so far been 
used in retrospective studies, and in particular in the description of surgical procedures.
27, 28
 
However, this framework is highly recommended for the application in the development of 
surgical innovations different from surgeries. This is important as the innovations are often 
introduced and developed only by manufacturers. Research ethics committees and device 
regulatory bodies could help by requiring a declaration of the IDEAL stage that the 
investigators/manufacturers feel the device or procedure has reached, with supporting 
evidence. Innovations in the idea stage, for instance, would then be expected to lead to 
proposals for a prospective development study. Thus, application of IDEAL would allow the 
setting of minimum requirements for developmental steps prior to market entry for any 
innovative product or device. As the current studies cover the topic of a surgical innovation, 
we followed the IDEAL recommendations in the entire investigation strategy and course in 
order to ensure comparability, visibility and confirmability. 
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3. MAIN GOALS 
There are currently no standardized tools for the comparison of surgical meshes. The 
initial purpose of our studies was to develop and standardize an in vitro test system with 
which to investigate biocompatibility features of surgical meshes. Once having developed 
this test system, we aimed to implement mesh-coating strategies and subsequently to 
investigate their influence on biocompatibility in in vitro performance. In order to explore the 
predictive value and validity of the test system and also newly tested coating strategies, we 
conducted a large-animal experiment in sheep. The entire approach followed the recently 
developed recommendations of IDEAL for surgical innovations.  
1. Study I. The main purpose was to investigate and develop an in vitro approach for an 
assessment of the biocompatibility features of surgical meshes. Seven different mesh types, 
currently used in various indications, were randomly selected and microscopically 
investigated after incubation for 6 weeks with regard to their adherence performance, using a 
tissue culture approach, with tissues representative of fibroblasts, muscle cells and 
endothelial cells, originating from 10 different patients.  
2. Study II. We aimed to investigate different mesh coating modalities with autologous blood 
components and their impact on the biocompatibility performance of the meshes in vitro, 
using the previously developed test system. Seven different mesh types were therefore coated 
prior to cultivation with autologous PBMCs, platelets and blood plasma and subsequently 
incubated for 6 weeks in a minced tissue assay. The adherence performance of the tissues on 
the meshes was investigated microscopically, assessed semi-quantitatively and compared 
with the native counterparts, using a previously developed scoring system. 
3. The goals of Study III and Study IV were to translate the preliminary in vitro results into 
an animal model in order to validate the in vitro test system and to explore its predictive 
value for in vivo surroundings. Three different meshes [TVT (Tension-free Vaginal Tape), 
UltraPro
®
 and polyvinylidene fluoride PVDF] with different previous in vitro performance 
scores were implanted in female sheep in a native or a plasma-coated version. In the ultra-
short-term study, meshes were explanted and investigated histochemically for inflammatory 
infiltrate, macrophage infiltration, vessel formation, myofibroblast invasion and connective 
tissue accumulation at the implant site at 5 min, 20 min, 60 min and 120 min. In the long-
term study, meshes were explanted after 3, 6, 12 or 24 months and processed. 
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4. MATERIAL AND METHODS 
4.1. In vitro experiments 
4.1.1. Meshes/Patients 
We randomly identified alloplastic materials currently applied as implants for 
different surgical indications covering hernia repair, POP and SUI. A total of 7 different 
meshes were investigated in this study. The meshes and their biomechanical/material 
characteristics are listed in Table 2. The alloplastic materials were prepared in 2 x 2 cm 
fragments for further investigations. Additionally, we harvested tissue probes of muscle, 
fascia and renal vein from 10 patients undergoing right-side nephrectomy. All patients gave 
their informed consent previously. The tissues and cells were processed identically in all 
patients. Each mesh was tested with the tissue and cells of each patient for comparison 
purposes. 
 
Table 2. Investigated meshes and their characteristics 
Mesh name Material Biomechanical characteristics 
Vitamesh
®
, 
ProxyBiomedical 
 
large-pore 
monofilament 
polypropylene 
knitted PP, pore size 2410 µm, thickness 
250 µm, tear resistance (Fmax N) 33.7 
Dynamesh
®
, FEG 
Textiltechnik 
 
monofilament PVDF effective porosity: 58%, reactive surface: 
1.97 m²/m², suture pull-out strength: 31 
N, tear propagation resistance: 28 N, pore 
size: 3000 μm 
TFT Motifmesh
®
, 
ProxyBiomedical 
micromachined PTFE pore size 235 µm, thickness 150 µm, tear 
resistance (Fmax N) 15.1 
TVT PP 
 
PP non-absorbable, permanent PP suture, 
pore size 164 x 96 μm 
UltraPro
®
, Hernia 
System Medium 
UHSM
®
, Ethicon 
PP reinforced with 
polyglecaprone fibers 
filament thickness 0.09 mm, mesh 
thickness 0.5 mm, Fmax N 69 N, pore size 
300 µm 
Proceed surgical 
mesh
®
, Ethicon 
 
monofilament PP 
encapsulated with 
polydioxanone (PDS) 
closely knitted with small pores < 1000 
µm size, high tensile strength 
 
Mersilene, Johnson & 
Johnson 
multifilament mesh, 
PET 
density 0.19 g/cm
3
, pore size 120-85 µm 
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4.1.2. Tissue preparation and mesh incubation 
In an initial cell culture approach involving investigation of the cells of the different 
tissues, we could not identify adherence on the mesh microscopically. In contrast, the cells 
grew on the bottom of the cell culture device. When performing a tissue culture, we observed 
tissue adherence both on the meshes and on the bottom of the cell culture device. As the cells 
did not grow on the respective mesh matrices, we decided to use tissue cultures for the 
following investigations. In addition, we considered tissue cultures more appropriate because 
of the reduced artificial modification processes due to the shorter culture processing. 
We extracted tissue probes originating from muscle, fascia and renal vein at a length 
of 0.5-1.0 cm each from 10 different patients. After crushing, we incubated the tissue with 
phosphate-buffered saline and, after 2 additional washing procedures, incubation was 
performed with DMEM/F12 plus 10% serum and 1% glutamine + 1% penicillin/stretomycin. 
After successful expansion and growth (80-90% adherent growth) of the tissue pellets, the 
different alloplastic materials were added. Thus, the prepared and expanded tissue probes 
consisting of myoblast, endothelial cells and fibroblasts presenting relevant tissues of the 
pelvic floor were used in vitro in order to create a model for investigation of the integrity of 
the different mesh types. Myoblasts were detected by α-sarcomeric actin and desmin as 
markers of myogene differentiation. Fibroblasts were stained with antibodies targeting 
vimentin, whereas antibodies against cluster of differentiation 34 (CD34) were used for the 
verification of endothelial cells. We reproduced every single approach 10 times with tissue 
probes from the 10 different patients. 
 
 
Figure 1. Microscopic adhesion course on PVDF: A) native prior to tissue culture, B) after a 
3-week tissue culture and C) after a 6-week tissue culture (time point of assessment). In B) 
and C) the spaces between the mesh filaments are increasingly occupied by fibroblasts, 
collagen deposits and capillaries. As adherence appeared 3-dimensionally, entirely defined 
pictures cannot be shown.
29
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4.1.3. Mesh coating 
PBMCs, platelets and plasma were used. PBMCs were separated through density 
gradient centrifugation using Ficoll.
30
 For the isolation of platelets and the respective 
mediators, the Advanced Tissue Regeneration System (ATR
®
 by Curasan Inc) was used 
(http://www.curasan.de/de/produkte/dental/atr/atr.php). The plasma preparation procedure 
followed the classical method of Crowley.
31
 After isolation of the 3 different blood 
components of each patient, we incubated the meshes (2 x 2 cm) with 10 ml of the respective 
suspension and incubated them for 12 h prior to testing with tissue. Successful plasma 
coating is exemplified in Figure 2. 
 
 
Figure 2. PVDF: A) native, B) after a 12-h plasma incubation, C) after a 12-h plasma 
incubation and trypan blue staining. In B and C the plasma is adherent to the mesh filaments, 
whereas the non-covered parts of the mesh appear native as in A.
32
 
 
4.1.4. Morphological study 
The adherence and the cell count (if possible) were assessed microscopically and 
through the use of immunohistochemistry after co-incubation of the cells with different types 
of alloplastic meshes. The test duration was 6 weeks. Meshes were investigated with regard 
to interstructural tissue connections and the quantity of mesh-adherent cells. Tissue cultures 
were maintained up to 4 months, with frequent changes of the medium, and assessment was 
repeated if possible. 
A descriptive/semiquantitive assessment pattern was used in order to describe the 
adherence of tissue to the investigated mesh materials. The assessment pattern was based on 
the maximum identifiable quantity of mesh-adherent cells within a tissue cluster per vision 
field. Adherence performance was ranked after assessment of the quality and quantity of the 
tissue clusters/cells as none, fair, good or excellent.
33
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4.2. In vivo experiments 
4.2.1. Animals 
The animal experiments were conducted at the Institute for Surgical Research of the 
University of Szeged, Hungary, in accordance with the NIH Guidelines (Guide for the Care 
and Use of Laboratory Animals). The experimental protocol was approved by the Animal 
Welfare Committee at the University of Szeged (license/permission No. V01353/2010).  
Fourteen 6-month old, female sheep weighing 20-25 kg were housed and cared for at 
the University farm for experimental animal studies. We included 2 animals more than the 12 
needed for safety calculations. All the animals had free access to food and water, and were 
cared for by an educated keeper and routinely inspected by a veterinarian. On the basis of the 
previously described test system and the resulting ranking, we selected 3 meshes representing 
good, intermediate and poor in vitro performance; PVDF, UltraPro
®
 and TVT (Table 3a). 
 
4.2.2. Mesh implantation  
Operations were performed on sheep in a supine position. The animals were intubated 
and an aspiration tube was introduced into the stomach. Anesthesia with Isoflurane 2% mixed 
with air and O2 (50/50%) was then established. Surgery was performed by using a 
longitudinal laparotomy. We chose 3 different locations in the sheep to implant the meshes 
via open surgery. In order to represent different in vivo surroundings, 3 meshes were placed 
in the following localizations: a) interaperitoneally, b) as fascia onlay and c) as muscle onlay 
(fascia sublay). The size of the implanted meshes was 3 x 5 cm. Then, 3 plasma-coated 
versions of the same mesh type were implanted in equivalent localizations on the 
contralateral side of the torso. Meshes had to be incubated with autologous plasma at least 12 
h prior to implantation. This procedure was performed in 14 animals, resulting in 4 animals 
per mesh type (plus 2 animals with PP TVT/PVDF). The mean operation duration was 1.5 h. 
For the short-term study, 3 additional female sheep weighing from 20 - 25 kg and at 
least 6 months old were included. The protocol for housing and veterinary maintenance was 
as in the long-term study. The size of the implanted meshes was 3 x 12 cm. For every native 
mesh implant, a respective plasma-coated version was implanted in an equivalent localization 
on the contralateral side of the torso. The length of incubation prior to surgery was at least 12 
h. We selected 1 sheep per investigated mesh, i.e. resulting in 3 animals. The investigated 
meshes were again PVDF, UltraPro
®
 and TVT. The chosen time points for explantation were 
5 min, 20 min, 60 min and 120 min. At each explantation time point, we dissected a piece 
about 3 x 3 cm in size from the initially implanted mesh. During implantation, the meshes 
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were fixed with 2 sutures at both ends. The mean operation duration for the implantation was 
50 min.  
 
Figure 3. Intraoperative sites during implantation: (A) intraperitoneal, (B) fascia onlay, (C) 
muscle onlay. 12 h prior to implantation the meshes were coated and incubated with 
autologous plasma. Meshes were implanted bilaterally into the torso to allow intraindividual 
comparison of coated versus uncoated meshes per animal. 
 
4.2.3. Mesh explantation 
After 3, 6, 12 and 24 months, three animals, respectively, underwent surgery for mesh 
explantation. The meshes were identified and then harvested, extent of local reactions was 
described macroscopically. The animals were sacrificed directly after mesh explantation and 
harvesting of probes of parenchymatous organs (liver, intestine, kidney, lung, heart). The 
harvested material was then assessed for foreign body reaction, scar formation and 
inflammatory reaction. For the short term study, explantation time points were 5 min, 20 min, 
60 min, 120 min, respectively. 
 
4.2.4. Morphological studies 
A single longitudinal section of mesh and adhesive tissue was obtained from each 
explanted mesh. Tissue samples were fixed in 10% formalin, and then sliced into 0.3 x 1 cm 
pieces and embedded in paraffin. In each case, 10 to 15 sections of 4 µm thickness were 
stained with hematoxylin and eosin (H&E), and with periodic acid-Schiff plus diastase and 
Elastica van Gieson. All mesh specimens were studied by light microscopy which was 
controlled by immunohistochemistry performed on the material embedded in paraffin, using 
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the avidin-biotin complex method with diaminobenzidine as a chromogen. The procedure 
was repeated twice for every sample. The antibodies used in this study included polyclonal 
rabbit anti-human CD3, 1:50, as pan-marker for T-lymphocytes (DAKO, Hamburg, 
Germany), polyclonal rabbit anti-human CD138, 1:50 as pan-marker for plasma cells 
(DAKO, Hamburg, Germany), monoclonal mouse anti-porcine CD68, 1:50 (DAKO, 
Hamburg, Germany), as pan-marker for macrophages, monoclonal anti-human CD15, 1:10 
(Becton Dickinson, Heidelberg, Germany) as marker for polymorphonuclear granulocytes, 
polyclonal rabbit anti-actin protein, 1:200 (DAKO, Hamburg, Germany) and monoclonal 
anti-CD34 1:200 (BIOMOL, Hamburg, Germany), as markers for fibromyocytes, and 
monoclonal porcine CD31, 1:10 (DIANOVA, Hamburg, Germany), as marker for endothelial 
cells. The morphometric evaluation consisted of a quantitative cell analysis of the 
inflammatory reaction and soft-tissue reaction. The cells were counted in each of in 5 H&E-
slides in 10 fields in a grid of 10 points (100x, area 0.1 mm
2
) and in the interface (0-300 mm, 
400x, area 625 mm
2). The parameters measured were the inflammatory infiltrate (µm), 
connective tissue (µm), vessels (%), macrophages (%), leukocytes (%), polymorphonuclear 
granulocytes (%), and fibroblasts (%), and TUNEL, Ki67 and HSP 70 expressing cells (%).  
 
4.2.5. Statistics 
All data were tested by ANOVA with the LSD modification according to Bonferroni. 
Statistical significance was set at p < 0.05. 
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5. RESULTS 
5.1. In vitro experiments 
5.1.1. Macroscopic results 
Overall, the macroscopic evaluation after tissue culturing did not disclose differences 
in the gross appearance of the meshes. Tissue culturing was successful in 100% of the probes. 
No signs of infection were observed throughout the entire cultivation course.  
 
5.1.2. Microscopic results 
The tissue growth was comparable in all approaches within a test duration of 6 weeks. The 
testing of the biocompatibility of myoblasts, endothelial cells and fibroblasts following the 
addition of BioGlue
®
 revealed unchanged tissue adherence to the mesh. Interindividual 
differences were not observed as concerns the growth and adherence performance after 
incubation with the different meshes in the investigated 10 patients.  
After 6 weeks, the investigated meshes were ranked according to the 
descriptive/semiquantitative approach described by Melman et al.
33
 The Melman score 
classifies tissue/cellular ingrowth on meshes as follows: none (0 point): no tissue ingrowth; 
fair (1 point): thin bands of fibroblasts and small collagen deposits between the mesh 
filaments; good (2 points): moderately thick bands of fibroblasts / collagen deposits between 
mesh filaments; excellent (3 points): nearly all the spaces between the mesh filaments are 
occupied by fibroblasts, collagen deposits and capillaries. 
The ranking is shown in Table 3a. Interestingly, after 4 months of tissue culturing the 
adhesion performance was comparable for all the meshes. Table 3b and Figure 4 present the 
ranking of the investigated native meshes and the different coating modifications. 
The entire experiment was reproduced as described and a modified Melman score was 
subsequently used for the 3 different coating approaches for each patient. Analysis of the 
PBMC-incubated meshes indicated tissue ingrowth comparable to that for the native mesh. 
Interestingly, the meshes previously incubated with ATR
®
 (Curasan Inc) and the plasma-
coated meshes exhibited a slightly better performance. This trend was reproduced after 4 
months of tissue culturing. All individuals displayed comparable effects of tissue ingrowth in 
the native state and after coating with the different blood components. 
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Table 3a. In vitro ranking of native meshes
29
 
Ranking Mesh type Adherence score 
 
1 Dynamesh
®
, FEG Textiltechnik 2.2 
2 TFT Motifmesh
®
, ProxyBiomedical 2.0 
3 Vitamesh
®
, ProxyBiomedical 1.6 
4 UltraPro
®
, Hernia System Medium UHSM
®
, Ethicon 1.4 
5 Mersilene Band, Johnson & Johnson 1.2 
6 Proceed surgical mesh
®
, Ethicon 1.2 
7 TVT PP 1.0 
 
 
Table 3b. In vitro ranking of meshes after coating with different blood components
32
 
Mesh type Native PBMCs ATR Plasma 
 
Dynamesh
®
, FEG Textiltechnik 2.2 2.1 2.6 2.7 
TFT Motifmesh
®
, ProxyBiomedical 2.0 2.0 2.3 2.7 
Vitamesh
®
, ProxyBiomedical 1.6 1.4 1.7 1.9 
UltraPro
®
, Hernia System Medium UHSM
®
, Ethicon 1.4 1.4 1.6 1.6 
Mersilene Band, Johnson & Johnson 1.2 1.2 1.4 1.5 
Proceed surgical mesh
®
, Ethicon 1.2 1.1 1.4 1.5 
TVT PP 1.0 1.1 1.4 1.6 
 
Tables 3a and 3b. For assessment of the adherence score after 6 weeks, we evaluated each 
mesh with tissues from 10 different patients. After semiquantitative determination, we 
obtained the frequency distribution of the score results for each mesh (points/10). The 
scoring was based on the classification proposed by Melman et al.
33
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Figure 4. Melman score comparison for different mesh coating modalities. The frequency 
distribution (y-axis) of the modified Melman score for each mesh is compared with the 
respective coating among the investigated 7 meshes.
32
 
 
5.2. In vivo experiments 
After the surgical implantation procedure we did not see major complications in the 
animals during the long-term study during 24 months. Only in 1 sheep did a seroma occur, on 
day 3 postoperatively, which had to be drained. All the animals survived and gained weight 
during the investigation period. At each explantation time point, we excluded zoonoses 
microbiologically through vaginal, nasal and oral smears. There were no clinical infections or 
mesh-related complications during the follow-up. We explanted the meshes after 3, 6, 12 or 
24 months. In the microscopic investigation of the different mesh reactions after explantation, 
the main focus was on the parameters measured for inflammatory infiltrate, connective tissue 
and macrophages (CD68). The respective quantifications are demonstrated in Tables 4a-c. 
For each explantation time point, we observed the same tendency in the investigated 
parameter (Figures 5a-c). High levels of connective tissue reaction and inflammatory 
reaction were assumed as indicative of a reduced biocompatibility. The ranking originating 
from the in vitro test system was reproducible, characterizing PVDF as the mesh (among the 
3 meshes investigated) with the least FBR, scar formation and inflammatory reaction at every 
individual time point. Reinforced PP (UltraPro
®
) was in second and PP (TVT) in third 
position. This constant ranking was repeated throughout the entire experiment. Moreover, the 
modified coated versions of the 3 meshes revealed the same result at a lower level of the 
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respective reactions (Figures 5a-c). The entire experiment suggested a beneficial effect of 
plasma coating prior to implantation, as shown in Figures 6a-c. The extent of improvement 
remained variable in the different meshes. 
 
Table 4a. In vivo course of inflammatory infiltration. Average values and standard deviations 
are shown for every measurement (thickness of the infiltrate in μm). 
 
Table 4b. In vivo course of connective tissue infiltration. Average values and standard 
deviations are shown for every measurement (thickness of the infiltrate in μm). 
 
Table 4c. In vivo course of macrophages (CD68).  
 
 3 months 6 months 12 months 24 months 
Mesh Native Coated Native Coated Native Coated Native Coated 
UltraPro
®
 25±11 20±8 24±7 19±5 21±10 17±4 22±11 18±6 
TVT 35±12 33±10 32±8 30±6 33±14 26±9 28±8 28±12 
PVDF 20±9 16±4 21±9 17±8 14±9 13±6 15±6 12±2 
 3 months 6 months 12 months 24 months 
Mesh Native Coated Native Coated Native Coated Native Coated 
UltraPro
®
 33±18 24±4 32±7 24±11 40±19 33±12 38±13 34±7 
TVT 37±12 30±17 36±8 28±12 43±14 20±19 41±10 24±12 
PVDF 25±12 19±7 22±9 23±10 22±9 17±9 24±5 19±3 
 3 months 6 months 12 months 24 months 
Mesh Native Coated Native Coated Native Coated Native Coated 
UltraPro
®
  34±6 34±9 28±11 26±12 25±6 19±4 22±4 18±6 
TVT 36±12 26±11 33±9 19±3 23±4 18±5 20±6 21±7 
PVDF 24±4 22±8 18±7 16±3 18±8 14±2 16±5 15±1 
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During the ultra-short-term study, neither minor nor major complications were 
encountered during surgery. In addition, no macroscopic differences were observed between 
the native and plasma-coated meshes immediately after explantation. As in previous studies, 
the main focus was on parameters measured for inflammatory infiltrate, connective tissue, 
macrophages (CD68) and endothelial cells as markers for vascularization and myofibroblasts 
in the microscopic investigation of the different mesh reactions after explantation. High 
levels of connective tissue reaction and inflammatory reaction were assumed to be indicative 
of a reduced biocompatibility. Figures 7 a-b graphically demonstrate and relate the short-
term and long-term courses of 5 important markers for early FBR determination. 
Within the first 2 h after implantation, an early invasion of macrophages at a 
comparable extent was observed in all meshes, culminating after 120 min. The induced 
inflammatory reaction expressed by the extent of inflammatory infiltrate revealed the same 
trend, but increased slowly. Macrophage invasion was detectable after 20 min at a relatively 
high level of about 50%, and increased slightly up to 70%. Interestingly, the macrophage 
invasion was highest in the PVDF meshes, which in the long-term approach performed best 
with lowest chronic inflammation. The respective early inflammatory infiltrate continuously 
increased within the first 60 min in all the investigated meshes. However, after 120 min this 
trend was reversed in the PVDF meshes. In contrast for TVT and UltraPro
®
 the inflammatory 
infiltrate was still increasing up to 120 min. Not surprisingly, no connective tissue was 
observed after 120 min. Additionally measured endothelial cells representative of vessel 
integration and myofibroblasts were all negative during the initial 120 min after implantation.  
Two markers, representative of early FBR signs, did show relevant activity within the 
first 2 h after mesh implantation. For those markers, therefore, inflammatory tissue and 
macrophage invasion, a comparison of the coated versus the uncoated version of the 
respective meshes was possible, but did not indicate relevant differences.  
Each mesh (coated and uncoated) was placed and investigated in 3 different positions 
of the torso (Figure 3). Differences regarding the reaction of the FBR determinants on the 
meshes were not observed either in the short-term or in the long-term approach when the 
different implant locations were compared. Further, the plasma coating did not influence the 
mesh performance in the different regions of the body. 
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Figure 5a.  In vivo ranking and validation. In vivo ranking of PVDF, PP (TVT) and 
reinforced PP (UltraPro
®
) meshes with regard to the extent of the inflammatory reaction. 
The ranking is depicted for the coated and native versions of the meshes. 
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Figure 5b. In vivo ranking and validation. In vivo ranking of PVDF, PP (TVT) and 
reinforced PP (UltraPro
®
) meshes with regard to the extent of the macrophage count. The 
ranking is depicted for the coated and native versions of the meshes. 
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Figure 5c. In vivo ranking and validation. In vivo ranking of PVDF, PP (TVT) and 
reinforced PP (UltraPro
®
) meshes with regard to the extent of connective tissue formation. The 
ranking is depicted for the coated and native versions of the meshes. 
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Figure 6a. Effect of plasma coating prior to implantation. A high level of connective tissue 
is related to a reduced biocompatibility. Statistically significant differences in the thickness of 
the connective tissue are indicated by an asterisk (*), corresponding to p < 0.05.  
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Figure 6b. Effect of plasma coating prior to implantation. A high level of inflammatory reaction 
is related to reduced biocompatibility. Statistically significant differences in the thickness of the 
inflammatory infiltrate are indicated by an asterisk (*), corresponding to p < 0.05.  
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Figure 6c. Effect of plasma coating prior to implantation. A high macrophage count is related 
to a reduced biocompatibility. Statistically significant differences in the percentage of the 
invading macrophages are indicated by an asterisk (*), corresponding to p < 0.05.  
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Figure 7a. Time course of investigated biocompatibility markers, relating ultra-short-term 
results to long-term results (during 24 months). 
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Figure 7b. Time course of investigated biocompatibility markers, relating ultra-short-
term results to long-term results (during 24 months). 
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6. DISCUSSION 
6.1. In vitro test system 
At present, many alloplastic materials are used without proper trials and are 
recommended by manufacturers rather than on the basis of data arising from in vitro or in 
vivo experiences. The standardized classification put forward by Amid in 1997 is one of the 
few tools which allows prediction of the biocompatibility performance of a surgical mesh.
4
 In 
that classification, importance is attributed to the pore size of the meshes as predictive of the 
expectable adverse event rate, suggesting that the classification should be taken into account 
when clinical decisions are made. Large porous meshes are currently regarded as the best 
tissue-integrative, with the least FBR, inflammation and fibrosis, whereas small-pore mesh 
modifications are associated with a significantly greater FBR and inflammation frequently 
related with the phenomenon of bridging, which may finally cause significant contraction or 
shrinkage of the mesh.
4
 
The aim of Study I was to investigate whether different tissues of the pelvic floor 
demonstrate different in vitro interaction characteristics with alloplastic materials currently 
used as meshes in different clinical indications, i.e. biocompatibility features rather than 
mechanical characteristics. Most of the meshes investigated in the present study consist of PP 
as basic material. We searched for a feasible and reproducible test system that allows the 
assessment and comparison of meshes with regard to their in vitro adherence scores to 
different tissues, as markers of their biocompatibility.  
The biocompatibility assessment of alloplastic materials through the use of 
appropriate cell cultures in vitro is a valid and accepted method which yields information 
about the toxicity of the investigated material, and possible effects on the metabolism and 
growth of the cells.
8
 Langer et al. investigated the cellular response of human fibroblasts 
cultured on different PP meshes, in particular with regard to the mesh material and 
structure.
34
 They used a method comparable to the one described here, implementing 
scanning electron microscopy. Their major conclusion was that the polymer surface and 
structure had a paramount influence on the biocompatibility of the meshes, as they identified 
fibroblasts preferably growing on low-weight meshes, thin filaments and mesh nodes. In 
contrast heavy-weight meshes were revealed to induce degenerative cell reactions resulting in 
a reduced biocompatibility. In contrast with Langer et al. we used a tissue culture approach, 
as our initial results with cell cultures did not reveal sufficient cell growth. Although 
investigation of the adherence of specific cells is useful, we consider that the co-incubation of 
implants with tissue clusters is comparable to in vivo processes. We can support the thesis of 
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Langer et al. that the microstructure of the meshes has a relevant impact on the growth and 
adherence behavior of cells imitating in vivo surroundings. Besides the presence of 
fibroblasts, we investigated muscle-derived and endothelial cells presenting relevant tissues 
of the pelvic floor. These observations resulted in a ranking of the investigated meshes as 
concerns their affinity for the co-incubated tissues/cells. Our ranking is in good accordance 
with the suggestions of Amid.
4
 However, material features other than pore size seem to play a 
role for the in vitro performance, explaining the different scores. Moreover, it emerged 
reproducibly that the adherence behavior was independent of the individual patient features, 
thereby supporting the idea that the biological behavior of a mesh in contact with host tissues, 
is mostly conditioned by the structure of the biomaterial or/and its chemical composition 
rather than by individual host characteristics/features. PVDF, a polymer with good textile and 
biological properties, displayed the best adherence performance in our test system. This 
polymer is currently applied as PVDF-coated PP mesh for intraperitoneal-only repair.
35, 36
 
The main characteristics of this mesh are its macroporosity, a decreased adhesion rate to the 
bowel and a favorable biocompatibility in vivo, with low rates of inflammation and fibrosis.
5
 
The good performance of PVDF in our test system is therefore not surprising. To date, 
reported investigations of the cellular reaction on meshes in humans are based on explanted 
meshes after complicated postoperative courses, resulting in negatively preselected 
alloplastic explants.
37
  
The test system presented here is far from being representative of an in vivo situation 
as the tissue culture was sterile and no probable physiological in vivo reaction, such as a 
FBR, inflammation, etc. was imitated. Another criticism may be aimed at the unselective 
investigation of the alloplastic materials. Meshes for POP, SIU or hernia repair definitely do 
not have identical biocompatibility/mechanical requirements. However, assumption of the 
adherence performance of tissue on a mesh as a possible marker of its biocompatibility seems 
logically independent of the respective clinical use of the implant. The test system may help 
to select particular alloplastic materials for further investigations, such as animal 
experiments, coating approaches (in vivo and in vitro), etc., as we reproduce comparable 
extents of cell adherence on specific meshes independently of the individual patient. Thus, at 
least in vitro, specific patient features do not seem to influence the adherence performance 
and respective biocompatibility of the alloplastic material. Although an exaggerated FBR 
tissue response is assumed to be related to clinical complications, a positive role in mesh 
incorporation at the implant site may be triggered by bioactive mediators such as epidermal 
growth factor, basic fibroblast growth factor or transforming growth factor and others 
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produced by fibroblasts or smooth muscle cells, for example. Thus the cultivation and 
positive adherence of cell clusters consisting of these cell types and the respective assessment 
and comparison, as shown here, may be helpful in the consideration of a mesh as regards its 
possible tissue ingrowth and capacity to form connective tissue. 
The in vivo behavior of a particular alloplastic material cannot be reliably extrapolated 
from in vitro studies, and appropriate in vivo approaches are therefore needed. The possible 
predictive value of these in vitro results with respect to cell and tissue adherence in vivo was 
the target in the following animal investigations. 
6.2. In vitro plasma coating 
Preclinical investigations of surgical innovations, e.g. meshes, in terms of bench 
and/or animal testing, are likely to represent a new standard requirement to confirm that 
engineering specifications are met and that the material and/or specific modification chosen 
for a mesh is sufficiently biocompatible. To date, there have been numerous reports of mesh 
modification approaches in order to improve their biocompatibility. The permanent character 
of a foreign body implant may cause persistent and increased inflammation, with ongoing 
collagen deposition leading to extensive fibrosis. The impaired host-acceptance of the 
implanted mesh is likely to appear through chronic inflammation and extensive fibrosis.
16
 In 
order to tackle the problem of extensive FBR initiated by early local inflammation, several 
researchers have modified the chemical and physical properties of meshes by different 
coating approaches resulting in altered local reactions and tissue responses, mostly by using 
in vivo experiments. Numerous compounds have been tested so far for mesh-coating 
purposes, the majority of them in in vivo models, mostly after setting a pathological defect to 
be repaired by the investigated meshes.
10, 11, 38-40
 Besides numerous in vivo experiments, 
Bryan et al. provide an in vitro model to facilitate the mesh choice in uncomplicated hernia 
repair by quantitatively determining neutrophil activation and degranulation in different mesh 
types.
41
 Their approach represents one of the few in vitro assessment tools for meshes 
currently available in the literature. In their experiments, reactive oxygen species (ROS), 
released by activated neutrophils and leading to non-specific host tissue damage and potential 
mechanical weakening were measured on the surface of 6 different meshes. They 
investigated native, non-modified meshes. They concluded that the mesh structure is a greater 
determinant of ROS release than the chemical composition. It seems likely that their 
sophisticated assay could also be used for mesh assessment after different coating 
approaches. This would be a conclusive further development comparable to the approach 
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presented here, which represents an advance on the initially described in vitro assessment 
tool for native meshes. 
The aim of our study was to implement and assess a facile mesh-coating procedure in 
vitro and to investigate whether the coating of meshes with autologous blood components 
shows different in vitro interaction characteristics with different tissues types as compared 
with native meshes. We used autologous blood components as they are relatively easy to 
obtain from the respective patients and contain relevant cells and substances involved in the 
humoral immune defense. This approach was based on the assumption that the extent to 
which an implanted alloplastic material elicits an acute local inflammatory response has an 
impact on the long-term outcome when applied in vivo.
42
 In order to investigate cellular and 
non-cellular components, we separately investigated PBMC, plasma and platelets with the 
respective mediators. Incubation with PBMCs did not result in modification of the adherence 
score for the investigated tissues. This may be explained by the reduced ability of these cells 
to maintain permanent contact with the polymer surface of the meshes, as previously shown. 
In contrast, blood plasma and ATR resulted in a better adherence performance and increased 
biocompatibility in all meshes. An interesting observation in the current study is that all 
meshes previously ranked with regard to their biocompatibility performance displayed an 
increased score after plasma coating and maintained their position in the ranking relative 
compared to the other investigated meshes. This supports the thesis that coating with plasma 
may have an effect independent of the mesh, and, at least in vitro, all meshes could improve 
their performance, but low-ranked meshes could not increase their position relative to 
natively better-positioned counterparts. The thesis of Bryan et al. can thereby be supported: 
the mesh structure seems to be an important determinant of the in vitro performance in the 
native and coated configuration of a mesh.
41
 Mesh-related complications are known to be 
related to extensive local inflammation, representing the first step of a FBR. This FBR after 
implantation of a mesh is assumed to be triggered by the secretion of a variety of proteins that 
attract inflammatory cells to migrate to the site of injury, finally leading to extracellular 
matrix regulation and collagen deposition. In a recent study, Brandt et al. investigated the 
effect of mesh coating (PVDF) with different substances affecting the cortisone metabolism. 
In their in vivo approach, they found that hydrocortisone and spironolactone protected from 
inflammatory response, ended up in smaller granuloma at the implant site of the mesh and 
decreased the collagen formation.
43
 Their approach suggested that the respective coating 
approaches are a possible way to attenuate local inflammatory processes in order to reduce 
the FBR. This is supported by other research groups who have reported altered local cell 
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activation and tissue responses after modifying the chemical and/or physical properties of 
meshes via coating, leading to the hypothesis that the coating of polymer surfaces may be an 
opportunity to improve mesh integration and biocompatibility.
44
 The assumption of the 
adherence performance of tissues on a mesh as a possible marker of its biocompatibility 
seems logical, independently of the respective clinical use of the implant. Although an 
exaggerated FBR/tissue response has been suggested to be related to clinical complications, a 
positive role in mesh incorporation at the implant site may be triggered by bioactive 
mediators such as epidermal growth factor, basic fibroblast growth factor or transforming 
growth factor and others produced by fibroblasts or smooth muscle cells, for instance. Thus, 
the cultivation and positive adherence of cell clusters consisting of these cell types and the 
respective assessment and comparison, as shown here, may be helpful for considering the 
possible tissue ingrowth and capacity of a mesh to form connective tissue. The coating of 
meshes with plasma and ATR appears to have a positive effect on those features. 
A main limitation of this study is that no inflammatory reaction as normally cascading 
in vivo was imitated as the in vitro approach was sterile. In conclusion, we conducted an 
animal investigation (Studies III and IV) in order to validate the in vitro results, for both 
native and coated meshes.  
6.3. In vivo validation 
The next step in the current approach was to translate the previous in vitro results into 
in vivo surroundings. In vitro models to investigate the biocompatibility features of alloplastic 
materials like meshes are limited with regard to their predictibility for in vivo surroundings. A 
mesh, per se, is a foreign body which induces a FBR. This FBR is triggered by the initial 
acute phase reaction and the subsequent construction of the implant matrix, mostly conducted 
by the migration of fibroblasts producing glycosaminoglycans and collagen. There is ongoing 
debate as to which implant-induced reactions are desirable and which are not. The 
development of new meshes should be based on a firm understanding of the mechanisms of a 
FBR.
45
 In our in vivo study, the histologic investigations for inflammatory infiltrates 
indicated a slight reaction associated with PVDF, which was increased in reinforced PP 
(UltraPro
®
) and even more so in PP (TVT). This reduced inflammatory reaction can be 
considered an expression of good biocompatibility. However, this observed postoperative 
sign of an inflammatory reaction was non-infectious, as counts for cells involved in the 
infectious immune defense, e.g. CD3, remained unaltered at low levels.
46
 In addition, when 
the connective tissue investigated, the same trend was observed: PVDF exhibited the thinnest 
layer of connective tissue, followed by reinforced PP (UltraPro
®
) and PP (TVT). There was a 
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macrophage decrease in all meshes during the postoperative follow-up, but the highest 
number of macrophages was seen in the TVT meshes and the in vitro ranking was consistent 
as regards this marker. Macrophages are key mediators involved in the foreign body immune 
reaction, suggesting that this reaction was stronger in PP (TVT) than in the other two applied 
meshes. As concerns the investigated parameters, macrophage invasion, inflammatory tissue 
and connective tissue formation, this study confirmed the previously established in vitro 
ranking of the 3 investigated meshes repeatedly throughout the entire animal experiment, 
after 3, 6, 12 and 24 months. Moreover, when the meshes were modified by pre-implant 
coating with autologous plasma, the ranking remained constant. This supports the assumption 
that the recently developed tissue culture in vitro test system for meshes is able to predict the 
in vivo performance of the meshes. Practically, the test system helps to distinguish between 
meshes with good and poorer healing performances. The previously described in vitro test 
system was sterile, and thus no physiological in vivo reaction such as FBR or inflammation 
could be imitated. This indicates that the adherence ability of a mesh is crucial for subsequent 
FBRs or inflammatory processes which determine the in vivo performance of the meshes. 
Moreover, as in the in vitro approach, we did not see individual recipient features that 
influenced the performance of the meshes. Besides material quality issues, we assume that 
the process which caused FBR to the meshes must have occurred in the early period, before 3 
months after implantation, since there was no further tendency to change during the 
following explantations. 
In a recent comparable long-term study in sheep, Zinther et al. investigated the 
shrinkage of an intraperitoneal onlay mesh using a coated polyester mesh versus a covered 
PP mesh.
47
 Besides the individual differences of the investigated meshes, they described a 
peak for shrinkage at 3 months, without additional shrinkage in the following 15 months, 
suggesting an early effect. This is in accordance with our results which indicate that an early 
process is responsible for the extent of a FBR and the mid- and long-term performance of an 
implanted mesh. This tendency is independent of the location of the mesh in the body, 
although its particular extent varies, depending on the site of implantation. Although those 
results must be confirmed in a larger series, this could be a novel approach to predict the 
bioperformance and integration of any available mesh, using a standardized in vitro 
experiment. 
Several animal studies have been proposed and reported for the investigation of local 
reactions after the implantation of a mesh graft. The present study is the first experimental 
study conducted in sheep, with a 2-year observation period. The use of sheep as an animal 
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model has various advantages. The biological behavior of human cells is comparable to that 
of the cells in the sheep model. As compared with other large animals, sheep demonstrate a 
limited growth potential, while the tendency to adhesion formation (intra-abdominally) is 
similar to that in humans.
48, 49
 In our study, we did not observe a specific reaction triggered 
by lymphocytes (B-lymphocytes and T-lymphocytes). Thus, it is very unlikely that the 
different lymphocyte status of sheep vs. humans may have had important influence on the in 
vivo biocompatibility performance. However, to exclude this potential bias, experiments in 
primates would be necessary, although very unrealistic. Given the mentioned advantages, the 
sheep model has the potential to serve as a template in future experimental mesh studies, in 
particular for the assessment of meshes in the abdominal cavity, but also other intracorporal 
locations. Data on adequate functional performance and material safety are currently at the 
focus of premarket reviews for mesh devices. Thus, preclinical investigations in terms of 
bench and/or animal testing are currently used to confirm that engineering specifications are 
met and that the material chosen for a mesh is biocompatible. Unfortunately, clinical 
performance data are rarely used to support clearance for meshes for whatever indication.  
In the study presented here, we could demonstrate the predictive value of our recently 
developed in vitro cell culture approach for the biocompatibility assessment of meshes when 
translated to in vivo circumstances. In a second attempt, we investigated coating approaches 
for meshes in order to improve their biocompatibility. In preliminary experiments, mesh 
coating with autologous plasma was shown to reduce FBRs both in vitro and in vivo. A 
plasma coating seems to have a consistent improving effect on the performance of the mesh 
as regards connective tissue development and inflammatory local reactions at the implant 
site, suggesting an improved biocompatibility.  
6.4. Foreign body reaction in the short term and the long term 
The main purpose of our large-animal study was to investigate in vivo 
biocompatibility predictors for 3 different meshes by measuring early and long-term signs of 
a FBR such as macrophage invasion, and inflammatory reaction and connective tissue 
determination at the implant site of the meshes. By relating the ultra-short-term data to the 
long-term data in the same species (i.e. sheep), we could show that the process of 
determination of a FBR is defined early in the course after implantation for markers of local 
acute inflammation. In contrast, myofibroblast invasion, vascularization and connective 
tissue adhesion are not relevantly presented in the ultra-short-term course. The extent of 
macrophage invasion and inflammatory tissue does not relevantly increase after 120 min as 
compared with the values for 3 months after explantation or later. Our previously described 
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method to improve the biocompatibility performance of meshes in vivo and in vitro by 
autologous plasma coating before implantation did not have an effect on the early 
inflammatory events, as the respective values for inflammatory infiltrate and macrophage 
invasion did not differ from coated to native meshes.
1, 29, 32
 However, markers such as 
connective tissue organization, myofibroblast invasion and endothelial cells, characteristic of 
vascularization, are detectable after 3 months post-implantation and show different extents in 
the 3 investigated meshes. 
To the best of our knowledge, our results reflect the longest combined short and long-
term in vivo approach to the investigation of biocompatibility issues on meshes. In addition, 
no ultra-short-term investigations in vivo have ever been reported so far, as most of the 
currently available studies investigated effects on meshes at the earliest after 7-21 days.
50
 It 
has been shown that an acute inflammatory reaction occurs at 7 days after implantation of a 
mesh, dominated by macrophage invasion.
51
 Over time, this early inflammatory process 
transforms into a chronic, at times granulomatous reaction, promoting wound healing, but 
also forming small granulomas.
16
 It is known that the extent of collagen formation may vary 
during this process, whereas a severe inflammatory reaction, with disordered fibrin and 
collagen deposition, is likely to compromise the integration process and functional outcome. 
In an investigation of prolene and a porcine dermal collagen implant (Pelvicol
®
), Zheng et al. 
identified a first acute-phase reaction after 48 h, peaking on day 7-14.
51
 Our data add ultra-
short-term information, suggesting that this reaction starts even earlier in the course, after a 
matter of minutes. Zheng et al. described that the acute reaction diminished and finally 
reached negligible levels by 90 days, which can be partially supported in our current study. 
FBRs to alloplastic mesh material are primarily induced by inflammatory cells such as 
macrophages and T-lymphocytes.
52, 53
 Macrophages have a critical role in acute inflammation 
and early vascularization, and also in the subsequent chronic phase of the host response, as 
they are known to be capable of differentiating toward two pathways. This M1/M2 
polarization enhances macrophages, leading to an immediate and/or persistent inflammation 
or to a constructive remodeling and new tissue generation.
54
 However, this polarization was 
not investigated in the current study. From the aspect of wound healing, it is known that 
CD68-positive macrophages reach their maximum level on the second day after injury and 
slowly decline thereafter.
55
 We have shown that high percentages of CD68-positive 
macrophages are detectable on the meshes after only minutes or hours. This could be of 
interest when investigating and developing mesh modification strategies to influence this 
early acute reaction. A previously developed plasma-coating strategy to optimize the 
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biocompatibility of meshes does not seem to influence this early inflammatory reaction and 
inflammatory infiltrate formation, but rather to influence mid- and long-term processes which 
lead to neovascularization and collagen fiber organization. It has been found that premature 
type III collagen is predominantly synthesized in the early phases of wound healing and in 
the presence of inflammatory cells.
56
 This type III collagen is then replaced by highly cross-
linked and stable type I collagen later after implantation. Delayed wound healing and 
immature scar development due to persistent chronic inflammation may be predicted by a 
lowered type I/III collagen ratio.
37, 57
 A favorable type I/III collagen ratio is known to 
improve biocompatibility and can be positively influenced by the pre-implantation of mesh 
modifications such as a gentamycin coating.
39
 As concerns the results of the present study, an 
increase in inflammatory infiltrate was revealed for all 3 meshes. After 120 min, PVDF was 
observed to increase considerably more slowly than TVT and UltraPro
®
. The previously 
shown good long-term biocompatibility performance of PVDF may hypothetically be 
triggered by an early decrease of the acute inflammatory reaction and subsequent 
modification of the micro-environment meshes, leading to an improved type I/III collagen 
ratio, for instance. We did not observe a direct influence of the localization of the implanted 
mesh in either the body in the short- or the long-term study as regards the reproducibility for 
the coated and uncoated meshes. Although the localizations were chosen to cover different 
structural parts of the body with different immunologic potentials and physical/mechanical 
strains, the localization does not seem to be of utmost importance for the biocompatibility 
performance of a mesh in vivo. 
6.5. The project with regard to the IDEAL recommendations and future perspectives 
A plethora of commercially available meshes currently make the decision as to which 
mesh to apply very difficult. Two FDA warnings in 2008 and 2011 reported more than 3,500 
severe adverse events after mesh applications, mostly in POP and SIU patients. As a 
consequence, the FDA recommended the consideration of regulatory changes, including an 
upgrading in risk classifications for meshes, clinical studies to address the risks and benefits 
of meshes and expanded the post-market monitoring of device performance.
58
 Our preclinical 
in vivo study was initially inspired by the first FDA warning of unexpected and severe 
adverse events during the use of mesh devices.
20
 We raised the question of whether the 
performance of a mesh would be predictable prior to its implantation in order to reduce the 
probability of unexpected mid- and long-term events as reported and complemented in 
2011.
21
 Although we did not selectively investigate meshes for the indications reported as 
POP and SIU, our system (in vivo and in vitro) may easily be used with every available mesh. 
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However, in a considerably narrow time frame as a reaction to the first FDA warning, we 
developed an in vitro approach, a subsequent animal study, and are now translating our 
results into a clinical trial. As a first step with this regard, we have analyzed and classified 
specific complications after vaginal mesh implantation approaches for prolapse repair.
59
 This 
analysis comprises the basis for a currently ongoing pilot study which is investigating the 
feasibility of the autologous plasma coating of meshes prior to implantation in humans. Thus, 
on the basis of the results presented in this work, we are applying for the first time plasma-
coated meshes in the human setting (Barski, Gerullis, Otto et al., 2014, unpublished data). As 
a next and most important step, a prospective randomized trial, possibly proving the positive 
effect of the plasma coating on the biocompatibility and morbidity outcome, is planned on the 
basis of the positive preliminary results. Both studies would fulfill stage 3/A of the IDEAL 
classification and consistently sustain the initially chosen way of implementing this new 
technology of plasma coating following IDEAL. 
In addition, and in order to provide the final stage 4/L step of the IDEAL approach, 
we are already creating and establishing an online platform for registration and outcome 
measurement of mesh application with clear definitions and classifications, which will be 
offered to the uro-gynecological community. We are therefore using well-described 
definitions for risk factors and possible complications based on ICS-IUGA standards in 
terminology and guidelines (Barski, Gerullis, Otto et al., 2014, unpublished data). 
These steps conform to the IDEAL recommendations and show how surgical research 
may be concluded (independently of any result) when strictly driven following standardized 
recommendations. McCulloch et al. specified recommendations concerning IDEAL for the 
field of urology.
60
 Although not mentioned in their review, we would add mesh-
implementing procedures for an interventional option as a topic of current controversy and 
debate in urology/uro-gynecology, not only for safety purposes, but also for effectiveness 
considerations.
61-64
 In conclusion, the current work displays the experimental in vitro and in 
vivo basis for the surgical innovation of a plasma coating on surgical meshes. The already 
completed and all planned stages of this innovation strictly follow the IDEAL 
recommendations. 
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7. SUMMARY OF FINDINGS 
 
1. We have developed a manufacturer-independent in vitro test system for the adherence 
performance of tissue clusters (fibroblasts, endothelial cells and muscle-derived cells) as a 
marker for the biocompatibility of commercially available meshes. In this test system, we 
established a repeatable ranking of meshes with regard to their biocompatibility. The 
adherence behavior was independent of the individual patient features, suggesting that the 
biological behavior of a mesh is probably conditioned by the structure of the biomaterial 
or/and its chemical composition rather than by individual host characteristics/features. 
 
2. The in vitro test system is a feasible pattern for the investigation of different coating 
strategies of meshes. The coating of meshes prior to cultivation with PBMCs, for instance, 
did not affect the adherence score, whereas coating with platelets and blood plasma increased 
the score, suggesting an improved biocompatibility in vitro. The plasma coating displayed the 
greatest potential to improve the in vitro adherence score. The previous ranking of the native 
meshes remained consistent after coating, but was established at a higher level. 
 
3. In a long-term animal study in sheep, we demonstrated that the developed in vitro test 
system for the biocompatibility of meshes may predict the in vivo performance of the meshes. 
This effect is independent of the location of the mesh in the body, although its particular 
extent varies depending on the site of implantation. The coating of meshes with autologous 
plasma prior to implantation seems to have a positive effect on the biocompatibility of 
meshes in vivo.  
 
4. Investigations of the ultra-short-term determinants of the FBR at the implant site in vivo 
revealed that the local inflammatory reaction is an early and susceptible event after mesh 
implantation. It cannot be influenced by prior plasma coating and does not depend on the 
localization of implantation. 
 
The development of this surgical innovation (the plasma coating of meshes prior to 
implantation) strictly followed the IDEAL recommendations at every step in order to ensure 
comparability and transparency.  
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